04:48 AM EDT, 08/06/2025 (MT Newswires) -- Novo Nordisk ( NVO ) reported Q2 earnings Wednesday of 5.96 Danish kroner ($0.92) per diluted share, up from 4.49 Danish kroner a year earlier.

Analysts polled by FactSet expected 5.92 Danish kroner.

Revenue for the quarter ended June 30 was 76.86 billion Danish kroner, compared with 68.06 billion Danish kroner a year earlier.

Analysts surveyed by FactSet expected 76.73 billion Danish kroner.

The company lowered its 2025 sales growth guidance to 8% to 14% from the previous range of 13% to 21% driven by lower growth expectations for its GLP-1 treatments in H2 2025. Analysts surveyed by FactSet expected 318.99 billion Danish kroner.